Head and Neck Cancer CA209-9TM

This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin.

Eligibility Criteria:

  1. Histologically proven squamous cell carcinoma of the head and neck (SCCHN) from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx
  2. Locally advanced disease which is unresectable, or resectable but suitable for an organ sparing approach
  3. No previous radiotherapy or systemic treatment for SCCHN

This study is for patients age 18 and older.

Available at: Hospital of Central Connecticut

Cancer Clinical Research Office